

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

DATE MAILED: 03/06/2003

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/728,534	11/28/2000	Merrill Goldenberg	A-576C	5310
7:	590 03/06/2003			
U.S. Patent Operations/ CAC			EXAMINER	
Dept. 4300, M/ AMGEN INC.	S 27-4-A		CHERNYSHEV, OLGA N	
One Amgen Center Drive				
Thousand Oaks, CA 91320-1799			ART UNIT	PAPER NUMBER
			1646	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
	Office Action Summers	09/728,534	GOLDENBERG ET AL.			
	Office Action Summary	Examiner	Art Unit			
	The season was a second	Olga N. Chernyshev	1646			
Period fo	The MAILING DATE of this communication app or Reply	pears on the cover sheet with the	correspondence address			
- Exte after - If the - If NC - Failu - Any	IORTENED STATUTORY PERIOD FOR REPL' MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.1. SIX (6) MONTHS from the mailing date of this communication. In period for reply specified above is less than thirty (30) days, a reply or period for reply is specified above, the maximum statutory period or treply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be till y within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from CAUSA the application to become APACAMEDIAN	mely filed ys will be considered timely. the mailing date of this communication.			
1)	Responsive to communication(s) filed on					
2a)⊠		is action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4)🖂	Claim(s) 1-5,8 and 13 is/are pending in the app	plication.				
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-5, 8 and 13</u> is/are rejected.						
7)	Claim(s) is/are objected to.					
8)	Claim(s) are subject to restriction and/or	election requirement.				
Application	on Papers	•				
9) 🗌 7	Γhe specification is objected to by the Examiner	•				
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority u	nder 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
	1. Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No					
 Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
	cknowledgment is made of a claim for domestic					
a)	☐ The translation of the foreign language prov cknowledgment is made of a claim for domestic	isional application has been rece	eived.			
1) Notice 2) Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal Page	(PTO-413) Paper No(s) atent Application (PTO-152)			
PTO-326 (Rev.	04.04)	on Summary	Part of Paper No. 10			

Application/Control Number: 09/728,534 Page 2

Art Unit: 1646

DETAILED ACTION

Response to Amendment

1. Claims 6-7 and 9-12 have been cancelled, claims 1-5 and 8 have been amended and claim 13 has been added as requested in the amendment of Paper No. 8, filed on December 23, 2002. Claims 1-5, 8 and 13 are pending and under consideration in the instant application.

- 2. The Text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 3. Any objection or rejection of record, which is not expressly repeated in this action has been overcome by Applicant's response and withdrawn.
- 4. Applicant's arguments filed on December 23, 2002 have been fully considered but they are not deemed to be persuasive for the reasons set forth below.

Double Patenting

5. Claims 1-5, 8 and 13 are rejected under the judicially created doctrine of obviousness-type double patenting over claims 108 of U. S. Patent No. 6,245,740 since the claims, if allowed, would improperly extend the "right to exclude" already granted in the patent for reasons of record as applied to claims 1-12 in section 11 of Paper No. 7.

Applicant submits that because of the amendment of the claims "as to specify that the compositions are prepared from a solution of G-CSF" as compared to the compositions prepared from G-CSF powder in '740 patent, then "[s]uch claims, if allowed, would not improperly extend the "right to exclude already granted in the patent" (page 8, second paragraph of the Response). This has not been found to be persuasive for the following reasons.

Art Unit: 1646

One of ordinary skill in the art readily understands that in order to prepare a G-CSF: polyol mixture it is reasonable to start with G-CSF solution rather than a powder because it would take less time and effort to mix these two ingredients together. It is also well known that sometimes G-CSF is available from the manufacturer as a solution, which was the case in Example 14, page 28 of the instant specification. Furthermore, it is also obvious that because the claimed composition is intended for pharmaceutical use, the proper dilution of the concentrated stock would be in order. There is no scientific reasoning known to suggest that a solution prepared from a concentrated solution of G-CSF and neat polyol would have different properties than a solution prepared from powdered G-CSF and, for example, 75% glycerol (Table 2, page 29 of the instant specification). Moreover, if polyol is represented by a fructose or sucrose, which can be presented in a form of a powder itself, it is not clear how to prepare a solution of G-CSF: fructose but by dissolving G-CSF first.

New grounds of rejection necessitated by amendment Claim Rejections - 35 USC § 112

- 6. Claims 1-5, 8 and 13 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
- 7. Claims 1 and 8 are vague and indefinite because it appears that the claims use terms "solution" and "mixture" interchangeably. It is clear from the instant specification that concentrated G-CSF solution was mixed with volumes of neat glycerol or different aqueous solutions of glycerol to prepare G-CSF/glycerol solutions (page 28, lines 9-25 and page 29,

Application/Control Number: 09/728,534

Art Unit: 1646

Table 2 of the instant specification). Furthermore, it is stated in the Response that "a <u>solution</u> of G-CSF could be mixed with pure glycerol to form a G-CSF: glycerol suspension" (page 7, last paragraph of the Response). Therefore, it is not clear what physical form of G-CSF/glycerol composition is intended by the claims. Clarification is required.

Claims 1 and 8 are further indefinite for recitation "a solution of G-CSF". There is no identification of a solvent and, therefore, the metes and bounds of the recitation cannot be determined from the claims or the instant specification.

8. Claims 2-5 and 13 are indefinite for being dependent from indefinite claims.

Conclusion

9. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Olga N. Chernyshev whose telephone number is (703) 305-1003. The examiner can normally be reached on Monday to Friday 9 AM to 5 PM ET.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on (703) 308-6564. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 782-9306 for regular communications and (703) 782-9307 for After Final communications.

Certain papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax center located in Crystal Mall 1 (CM1). The faxing of such papers must conform with the notices

published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)0. NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by Applicant or Applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers.

Official papers filed by fax should be directed to (703) 308-4556 or (703) 308-4242. If either of these numbers is out of service, please call the Group receptionist for an alternative number. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294. Official papers should NOT be faxed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Olga N. Chernyshev, Ph.D. March 4, 2003

JOHN ULM PRIMARY EXAMINER GROUP 1800